Alectinib for ALK-fusion tumors in children and teens
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests how safe alectinib is and how it works in children and teens with solid tumors or brain (CNS) tumors that have an ALK gene fusion. It’s for tumors that have come back, worsened, or don’t have a good standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must be confirmed to have an ALK gene fusion (from a test like F1CDx or prior gene sequencing).
- Your cancer must have relapsed or not responded to prior treatment, or there must be no satisfactory standard treatment available.
- The cancer must be measurable/evaluable with standard scan/assessment rules (RECIST, RANO, or related criteria).
- You must be able to provide tumor tissue for testing (new biopsy if needed, or stored tissue from diagnosis).
- You must have sufficient bone marrow health and be well enough to take part (age-based activity score about 50% or higher).
- You (and the caregiver) must be able and willing to do required study visits and assessments for the whole study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether it is better to delay brain radiation or give it right away in people with ALK-positive lung cancer that has spread to the brain and is causing few or no symptoms. If you are starting alectinib, you may be able to join and help find the best timing for radiation.
This study tests whether alectinib can treat ALK-positive cancers in adults, teenagers, and children. It focuses on people whose cancer testing shows an ALK change, and who can start oral treatment and have a new tissue sample.
This early-phase trial studies how alectinib (an ALK-blocking medicine) moves through the body and how it’s tolerated in people with advanced non-small cell lung cancer (NSCLC) that has an ALK rearrangement. You may be considered if you have ALK-positive, recurrent or advanced disease and have already had specific prior treatments.
This trial tests two targeted drugs (crizotinib or alectinib) for advanced bone cancers with an ALK gene change. These drugs are designed to block a specific protein that helps cancer cells grow, and may help if standard treatments haven't worked.
This trial tests giving alectinib first, then adding targeted radiation to remaining spots of cancer in people with ALK-rearranged advanced non-small cell lung cancer. It aims to control the cancer after an initial response and help keep disease from progressing.
This study looks at how well alectinib works when given after surgery to people with early-stage ALK-positive non-small cell lung cancer. It aims to understand real-world outcomes for patients who take this targeted therapy as their first treatment after surgery.
Hear when a new ALK Fusion-positive Solid or CNS Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.